Codice QR

Correlates of severe and delta COVID-19 in a phase 3 trial of the AZD1222 vaccine

Abstract In the phase 3 AZD1222 COVID-19 vaccine trial, anti-Spike (vaccine-matched and Delta) binding IgG antibody concentration and neutralizing antibody (nAb) titer (vaccine-matched+D614G and Delta), measured four weeks post-dose two (D57), were assessed as correlates of risk of severe COVID-19 a...

Descrizione completa

Salvato in:
Autori principali: Holly Janes, Youyi Fong, Ying Huang, David Benkeser, Elizabeth J. Kelly, Ian Hirsch, Ann Marie Stanley, Tonya Villafana, Christos J. Petropoulos, Andrew Leith, Deanne Haugaard, Bill Webb, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Lars W. P. van der Laan, Nima S. Hejazi, April K. Randhawa, Michele P. Andrasik, James G. Kublin, Margaret Brewinski Isaacs, Mamodikoe Makhene, Tina Tong, Merlin L. Robb, Lawrence Corey, Kathleen M. Neuzil, Dean Follmann, Ann R. Falsey, Magdalena E. Sobieszczyk, Richard A. Koup, Peter B. Gilbert, On behalf of the AstraZeneca AZD1222 Clinical Study Group, The Immune Assays Team, The United States Government (USG)/CoVPN Biostatistics Team
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Portfolio 2026-04-01
Serie:npj Vaccines
Accesso online:https://doi.org/10.1038/s41541-026-01411-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi